 Home > Medical News > Latest Medical News > Boehringer Ingelheim's first-in-class immune drug Spesolimab submitted a marketing application in China for the treatment of generalized pustular psoriasis

Boehringer Ingelheim's first-in-class immune drug Spesolimab submitted a marketing application in China for the treatment of generalized pustular psoriasis

 Last Update: 2021-12-09
 Source: Internet
 Author: User

Tags

drug compendia

salmonella infection symptoms

what drug interaction

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Shanghai, October 26, 2021/PRNewswire/ - On October 25, 2021, Boehringer Ingelheim announced that it has formally submitted a listing application for the new immune drug Spesolimab to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration , Used to treat the onset of generalized pustular psoriasis (GPP)
.

Previously, based on the superior performance of Spesolimab in its treatment of GPP Phase I and Phase II clinical trials, CDE has granted Spesolimab breakthrough therapy drug designation on June 25 this year

GPP is a rare, recurrent or persistent skin disease[i,ii].
According to statistics, only 1 to 2 of about 100,000 people in China suffer from GPP[iii]
.

GPP is different from psoriasis vulgaris.

In recent years, studies have found that pustular psoriasis is related to the interleukin-36 (IL-36) pathway
.

Spesolimab is a monoclonal antibody that blocks the IL-36 receptor.

Dr.
Zhang Wei, Head of Medicine and Clinical R&D of Boehringer Ingelheim Greater China, said: "We have been committed to accelerating the deployment of global innovative drugs in China, so that Chinese patients can benefit from them as soon as possible
.

Thanks to the reform of China's new drug approval system and the company With the implementation of the'China Critical' project, China has participated in and successfully completed Spesolimab's global pivotal Phase II clinical trial, enabling us to simultaneously submit applications for Spesolimab for the treatment of GPP onset indications in China

ii.

iii.

Source: Boehringer Ingelheim

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

single use technology(195)

united states logo(227)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.